TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00783042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral, once daily for 1 month (double blind)
Study: NCT02383446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elan foot prosthesis
Description: The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
Study: NCT01567488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide LAR
Description: 30 mg each 28 days
Study: NCT01849588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study: NCT02784301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belly breathing with biofeedback app
Description: This intervention consists of learning how to belly breathe using a smartphone biofeedback application that coaches children how to breathe slowly and deeply. The app consists of a cartoon avatar in a hot air balloon that inhales and exhales bubbles. The goal of the biofeedback game is to a) teach a voluntary deep breathing protocol, b) detect compliance to the breathing protocol using the attached audio-based pulse oximeter sensor and c) to raise the hot air balloon in accordance to this compliance in order to motivate the children. Scenery changes as the balloon rises, driven by biofeedback, until it eventually reaches outer space.
Study: NCT03479515

Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound, ADP, bioimpedance measurements
Study: NCT04558515

Intervention type: DIAGNOSTIC_TEST
Intervention: Novel malaria diagnostics & tools
Description: Next generation microscopy tools for malaria diagnosis and medical applications

Intervention type: DIAGNOSTIC_TEST
Intervention: Novel malaria diagnostics & tools
Description: Next generation microscopy tools for malaria diagnosis and medical applications
Study: NCT02784301

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Belly breathing without biofeedback app
Description: This intervention consists of learning how to belly breathe without the biofeedback application prior to the blood collection and continuing with self-directed belly breathing during the procedure itself.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Belly breathing + visual distraction
Description: This intervention consists of learning how to belly breathe without the application plus receiving visual distraction by watching a cartoon avatar in the hot air balloon rising through space. The avatar will not coach the child to breathe as the visual cues for breathing (words and bubbles) will not be present and the avatar will not rise in response to correct belly breathing. Participants will be instructed to continue with self-directed breathing while also watching the visual distraction during the blood collection procedure.
Study: NCT02871375

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A multifocal contact lenses
Description: Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A multifocal contact lenses
Description: Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual multifocal contact lenses
Description: Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual multifocal contact lenses
Description: Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality
Study: NCT03460522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: Patients will receive standard of care chemotherapy (only maintenance) after Inotuzumab Ozogamicin.
Study: NCT03192839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose PUFA
Description: Low dose PUFA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dose PUFA
Description: High dose PUFA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03592121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: Apply approximately 1 hour prior to sexual activity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Apply approximately 1 hour prior to sexual activity
Study: NCT00004412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine Butyrate
Description: To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.

Intervention type: DRUG
Group type: OTHER
Intervention: Arginine Butyrate
Description: To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard local care dressing
Description: To heal leg ulcers.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard local care dressing
Description: To heal leg ulcers.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard local care dressing
Description: To heal leg ulcers.
Study: NCT03501732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values Affirmation
Description: Experimental Group selects two values and describes why they are important

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk Feedback
Description: Experimental and comparator conditions both receive normative feedback in domains of risk

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Feedback
Description: Experimental and comparator conditions both receive normative feedback in domains of risk
Study: NCT00268918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants may continue receiving study drug as long as their disease does not worsen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787
Description: Participants may continue receiving study drug as long as their disease does not worsen
Study: NCT04410718

Intervention type: OTHER
Intervention: Glycaemic levels
Description: Glycaemic levels during admission for COVID-19

Intervention type: OTHER
Intervention: Glycaemic levels
Description: Glycaemic levels during admission for COVID-19
Study: NCT00313417

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate
Description: Up to 10 grams

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in the same way and appearance as the active treatment
Study: NCT04327102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education tools combined with health literacy intervention
Description: On the basis of the control group, the intervention measures to improve the health literacy of patients were implemented and self-made health education tools were used. During hospitalization, health knowledge lectures shall be organized for patients. Before the activity, the theme of the activity shall be clarified. Each participant shall be organized by the educator to sit on the tool chart in a U-shape. According to the theme of the tool map, patients interact with educators. And learn the knowledge content related to hypertension health literacy. Before the end of the activity, the educator will review all the contents discussed in the activity quickly, answer the questions in the activity, and help the participants to sort out and consolidate the knowledge acquired in the education. Follow up intervention for patients after leave hospital.
Study: NCT02637583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Intramuscular injection of 13-valent pneumococcal conjugate vaccine once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Intramuscular injection of 13-valent pneumococcal conjugate vaccine once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPV23
Description: Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once
Study: NCT04851626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnotic intervention for persistent pelvic pain.
Description: Education about persistent pelvic pain followed by 7 recordings of hypnosis intervention across 7 weeks accessed online through recordings.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group persistent pelvic pain no intervention.
Description: Control group no hypnotic intervention. Waitlist control.
Study: NCT02893241

Intervention type: DRUG
Intervention: Cafedrine/theodrenaline

Intervention type: DRUG
Intervention: Cafedrine/theodrenaline

Intervention type: DRUG
Intervention: Ephedrine

Intervention type: DRUG
Intervention: Ephedrine
Study: NCT04531761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Support Program
Description: The parent support program includes three modules aimed at increasing knowledge, positive attitudes, and supportive behaviors towards trans youth. Each online module includes several activities including writing prompts, videos, interactive quizzes, and other educational activities.
Study: NCT05076201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patients with completed rehab
Description: The main objective is to measure the level of cocaine craving, 6 months after the end of their detoxification treatment (outpatient or full hospitalization), in patients with a diagnosis of moderate to severe dependence (DSM 5) to cocaine and co-addiction, or not, to alcohol and / or psychostimulants. To evaluate cocaïne craving,the questionnaire CCQ-Brief will be used.
Study: NCT02300363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (rosuvastatin)
Description: 10 mg rosuvastatin administered on Day 1 and Day 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (LX4211)
Description: 400 mg LX4211 administered on Day 7 through Day 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)
Description: 10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13
Study: NCT00117143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.
Study: NCT02142530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Study: NCT03872180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT04262336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DB-020
Description: Injectable sterile viscous solution of DB-020 and sodium hyaluronate in sterile water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DB-020
Description: Injectable sterile viscous solution of DB-020 and sodium hyaluronate in sterile water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Injectable sterile viscous solution of sodium hyaluronate in sodium chloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Injectable sterile viscous solution of sodium hyaluronate in sodium chloride
Study: NCT02639364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nellcor Puritan Bennett 840 ventilator system
Description: Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nellcor Puritan Bennett 840 ventilator system
Description: Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.
Study: NCT03302702

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise program
Description: Exercise program including breathing control, pursed-lip breathing, diaphragmatic and thoracic breathing, aerobic and strengthening training
Study: NCT04340882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study: NCT00143611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resatorvid
Description: Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resatorvid
Description: Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
Study: NCT04358497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic® Concerto® detachable coil system
Description: coil embolization of the reflux pathways

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sclerosis
Description: Pelvic varices sclerosis with polidocanol foam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin / Hesperidin
Description: Best chronic medial treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmin / Hesperidin
Description: Best chronic medial treatment
Study: NCT01005186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating habits, diet and exercise
Description: Programme of change to eating habits, diet and exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating habits, diet and exercise
Description: Programme of change to eating habits, diet and exercise
Study: NCT03682211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: 50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulphate
Description: 10 mg/ml Morphine sulphate BP (Antigen Pharmaceuticals, Marketing Authorisation No.PA 73/20/1) administered intravenously.
Study: NCT04358497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: NSAID treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: NSAID treatment
Study: NCT04237961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botox and brow lift
Description: Botox injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection
Description: Fat injection and botox

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture
Description: Suspension suture
Study: NCT01521026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: 12-week compensatory cognitive training in group format
Study: NCT02348125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitochondrial Cocktail
Study: NCT04236388

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone drink
Description: Pre- and post-testing will be completed before and after participants receive 42 doses of ketone supplement drink over a 2-week period (3x/day for 14 days).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Pre- and post-testing will be completed before and after participants receive 42 doses of placebo supplement drink over a 2-week period (3x/day for 14 days).
Study: NCT01402817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent®/Sunitinib
Description: Upon enrollment, subjects will receive Sutent® orally. Adults (Age \>18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
Study: NCT00502671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1250mg/m2 po bid on days 1-14 of each 3 week cycle
Study: NCT01179581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose, oral solution or capsule (matching corresponding study medication)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: multiple dose, capsule, 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple dose, capsule, 10 days
Study: NCT03627156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guided counseling
Description: Community-based guided counseling using Health Belief Model and Theory of Planned Behavior is the intervention package for this study.
Study: NCT04065685

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: serious game named Go Wish
Description: The nurse led intervention Go Wish is composed of 36 cards presenting statements of personal needs, values, and beliefs about end-of-life care. The aim is to decide about what to put into the patient's file as care options and the subsequent appointments to name a potential surrogate or to elaborate ADs.~Patient and relative (if participating) will meet their nurse twice:~Session 1: patient the cards in three piles and to rank the ten most important. Session 2 without relative: the nurse reiterates the wishes of care and treatments previously expressed and links them to the state of health and symptoms of the patient and the current treatments and their possible evolution.~Session 2 with a relative: the relative sort the cards based on his/her beliefs about the patient's expectation.~Session 3 with a relative: the nurse bring together the patient and his/her relative to discuss the priorities selected independently, identify, and explore the similarities and differences.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: serious game named Go Wish
Description: The nurse led intervention Go Wish is composed of 36 cards presenting statements of personal needs, values, and beliefs about end-of-life care. The aim is to decide about what to put into the patient's file as care options and the subsequent appointments to name a potential surrogate or to elaborate ADs.~Patient and relative (if participating) will meet their nurse twice:~Session 1: patient the cards in three piles and to rank the ten most important. Session 2 without relative: the nurse reiterates the wishes of care and treatments previously expressed and links them to the state of health and symptoms of the patient and the current treatments and their possible evolution.~Session 2 with a relative: the relative sort the cards based on his/her beliefs about the patient's expectation.~Session 3 with a relative: the nurse bring together the patient and his/her relative to discuss the priorities selected independently, identify, and explore the similarities and differences.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Standardized information on anticipated directives (ADs): the imad nurse are trained to promote AD to clients to help nurses to describe and explain ADs, to identify and to mobilize the required interview condition to promote ADs to clients to facilitate and initiate discussion on ADs
Study: NCT03119051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online cognitive training
Description: A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.
Study: NCT03932942

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: QIAstat at pediatric emergency room
Description: Pediatric acute care nurses will obtain respiratory samples for testing from all patients with fever or any respiratory symptom.
Study: NCT03119051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training plus physical exercise
Description: Online cognitive training A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.~Physical Exercise Tai Chi Training：a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction.
Study: NCT02163499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate
Description: Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
Study: NCT00591448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: See above
Study: NCT01186185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: Fludrocortisone 0.2 mg by mouth daily for 30 days